Hosted on MSN24d
Verismo doses first subject in Phase I trial of SynKIR-310
Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310. The subject was dosed at the Sarah Cannon Research Institute of Colorado ...
The SandPaper8d
Puccini’s ‘Madama Butterfly’ to Be Performed at Stockton PAC
The New Jersey Association of Verismo Opera will perform Giacomo Puccini’s “Madama Butterfly” at 7:30 p.m. on Friday, Feb. 7 ...
Technical24d
Philly weekly roundup: Sixers deal struck down; Verismo Therapeutics $4M grant; Ghost Robotics settles lawsuit
Read on for Technical.ly’s weekly roundup of top news in the region. • Penn Spinout Verismo Therapeutics received a $4 million investment from the Institute for Follicular Lymphoma Innovation. The ...